Is Raptor Pharmaceuticals Ready to Roar?
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Raptor Pharmaceuticals (NAS: RPTP) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Raptor and see what CAPS investors are saying about the stock right now.
Co-Founder/CEO Dr. Christopher Starr
Return on Capital (average, past 3 years)
$43.1 million / $23.4 thousand
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 96% of the 50 members who have rated Raptor believe the stock will outperform the S&P 500 going forward.
I'm a long-term skeptic on Raptor, but I believe the stock is due for a turn-around before the DR Cysteamine PDUFA for cystinosis on January 30. Will convenience and a reduction in side effects convince insurers to pay 10-20 times as much as they pay now for the current therapy? I doubt it, and I don't think traders buying into the PDUFA will stick around to find out. Far-fetched use of the same compound for Huntington's disease and NASH is still in pie-in-the-sky stage and won't provide much lift until late 2013. This is a quick ditch if I have a positive score going into the PDUFA.
If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a perfect five-star rating, Raptor may not be your top choice.
We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
The article Is Raptor Pharmaceuticals Ready to Roar? originally appeared on Fool.com.Fool contributor Brian Pacampara has no positions in the stocks mentioned above. The Motley Fool owns shares of AstraZeneca. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.